Darolutamide plus ADT delays pain progression in metastatic hormone-sensitive prostate cancer
New treatment delays pain in advanced prostate cancer
This randomised, double-blind, phase 3 trial in men with metastatic hormone-sensitive prostate cancer found that darolutamide plus androgen …
Men with advanced prostate cancer who took darolutamide stayed pain-free longer and felt better overall for months compared to those on stan…
Phase II trial of CyberKnife SBRT and androgen deprivation therapy in unfavorable intermediate- to high-risk localized prostate cancer
Small trial shows CyberKnife radiation plus hormone therapy is well tolerated for high-risk prostate cancer
This Phase II trial evaluated CyberKnife-based SBRT with simultaneous integrated boost and androgen deprivation therapy in 20 patients with …
A small study of 20 men with high-risk prostate cancer found that CyberKnife radiation plus hormone therapy was well tolerated with low rate…
MRI-RSI changes during neoadjuvant ADT and radiotherapy in men with high-risk localized prostate cancer
Early MRI scans shrink after treatment to help spot prostate cancer recurrence sooner
This prospective phase II trial protocol reports early results from 97 men with unfavorable-intermediate-risk or high-risk localized prostat…
New MRI scans taken before and during treatment for prostate cancer show clear shrinkage that could help doctors target the tumor more accur…
Systematic review finds neoadjuvant chemohormonal therapy improves biochemical progression-free survival in locally advanced prostate cancer
Chemo Before Prostate Surgery Linked to Better Cancer Control
This systematic review and meta-analysis evaluated neoadjuvant chemohormonal therapy (NCHT) combined with radical prostatectomy versus radic…
Patients with advanced prostate cancer may see better cancer control with chemo before surgery, though survival gains need more proof.
Expert panel agrees on early detection and ARPI/ADT role for high-risk prostate cancer BCR
Experts agree on some approaches for high-risk prostate cancer recurrence but disagree on timing
An expert opinion review summarized panel discussions on managing high-risk biochemical recurrence in prostate cancer.
Experts agree on early detection and medication use for high-risk prostate cancer recurrence but disagree on the best timing for starting tr…